Theravance Biopharma, has announced that new interim data from the company's ongoing Telavancin Observational Use Registry (TOUR) study will be the focus of an oral presentation at the Society of Critical Care Medicine's (SCCM) 46th Critical Care Congress.
TOUR is designed to assess how Vibativ (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings. Data being presented will focus on a subset of registry patients with diagnoses of bacteremia or infective endocarditis. The SCCM 46th critical care congress is being held in Honolulu, HI on January 20-25, 2017.
TOUR is a multi-center, observational study designed to enroll and report the treatment course of approximately 1,000 patients from about 50 sites in the US. As a non-interventional study, all treatment decisions are at the discretion of the patient's healthcare provider. Study patients may have treatment initiated in either hospital-based settings or out-patient infusion sites. In order to qualify for enrollment in TOUR, patients must have received at least one dose of Vibativ and meet specified inclusion criteria. By broadly collecting and examining real-world data related to Vibativ treatment patterns, clinical effectiveness and safety outcomes in medical practice, Theravance Biopharma aims to create an expansive knowledge base to guide optimal clinical use and future development of the drug.
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. The internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Vibativ, the first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease. Neprilysin (NEP) inhibitor programme is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. The research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first programme to emerge from this research is designed to develop GI-targeted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.